<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Buprenorphine</id>
	<title>Buprenorphine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Buprenorphine"/>
	<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Buprenorphine&amp;action=history"/>
	<updated>2026-04-05T06:03:33Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Buprenorphine&amp;diff=1785&amp;oldid=prev</id>
		<title>Treloars: Created page with &quot;==Section 8 - MEDICATION GUIDELINES== ===ANTICONVULSANT===  ====Buprenorphine ==== &#039;&#039;&#039;DESCRIPTION / ACTION:&#039;&#039;&#039; * Medication to treat opioid use disorder (OUD) &#039;&#039;&#039;INDICATIONS:&#039;&#039;&#039; * Patients precipitated opioid withdrawal who agree to start recovery and agree to transport to a designated CORE transport facility &#039;&#039;&#039;CONTRAINDICATIONS:&#039;&#039;&#039; * Severe hypersensitivity, including anaphylaxis and angioedema &#039;&#039;&#039;DOSE:&#039;&#039;&#039; * 8mg Sublingual Tablet as per Protocol  Category:Medication...&quot;</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Buprenorphine&amp;diff=1785&amp;oldid=prev"/>
		<updated>2024-12-03T19:02:41Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Section 8 - MEDICATION GUIDELINES== ===ANTICONVULSANT===  ====Buprenorphine ==== &amp;#039;&amp;#039;&amp;#039;DESCRIPTION / ACTION:&amp;#039;&amp;#039;&amp;#039; * Medication to treat opioid use disorder (OUD) &amp;#039;&amp;#039;&amp;#039;INDICATIONS:&amp;#039;&amp;#039;&amp;#039; * Patients precipitated opioid withdrawal who agree to start recovery and agree to transport to a designated CORE transport facility &amp;#039;&amp;#039;&amp;#039;CONTRAINDICATIONS:&amp;#039;&amp;#039;&amp;#039; * Severe hypersensitivity, including anaphylaxis and angioedema &amp;#039;&amp;#039;&amp;#039;DOSE:&amp;#039;&amp;#039;&amp;#039; * 8mg Sublingual Tablet as per Protocol  Category:Medication...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Section 8 - MEDICATION GUIDELINES==&lt;br /&gt;
===ANTICONVULSANT===&lt;br /&gt;
&lt;br /&gt;
====Buprenorphine ====&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;DESCRIPTION / ACTION:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Medication to treat opioid use disorder (OUD)&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;INDICATIONS:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Patients precipitated opioid withdrawal who agree to start recovery and agree to transport to a designated CORE transport facility&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;CONTRAINDICATIONS:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Severe hypersensitivity, including anaphylaxis and angioedema&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;DOSE:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* 8mg Sublingual Tablet as per Protocol&lt;br /&gt;
&lt;br /&gt;
[[Category:Medication Guidelines|Buprenorphine]]&lt;/div&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
</feed>